AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of the Medullary Microenvironment in Acute Childhood Leukemia

RecruitingNAAges 1 Year - 15 YearsAllUniversity Hospital, Tours
💬

In plain words

What the trial is, and whether it could suit you

Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * for patients with AL: 1. Child with acute lymphoblastic or myeloblastic leukemia at diagnosis 2. Not having received prior hematological treatment 3. Aged 1 to 15 years old 4. Whose 2 parents, or the holder of parental authority, have signed a consent enlightened. 5. Affiliated patient or beneficiary of a social security scheme. * Control group patients: 1. Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis). 2. Aged between 1 and 15 years old. 3. Having no pathology of hematological origin. 4. Not having received any treatment that could interfere with the functioning of the bone marrow. 5. Whose 2 parents or the holder of parental authority have signed a consent enlightened. 6. Affiliated patient or beneficiary of a social security scheme. Exclusion Criteria: * for patients with AL: 1. Patient under 1 year old and over 15 years old. 2. Contraindication to myelogram. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Patients with relapsed acute lymphoblastic or myeloblastic leukemia. 5. Having received prior hematological treatments. 6. Parents with physical or mental condition not allowing to understand the informed consent. * Control group patients 1. Patient under 1 year old and over 15 years old. 2. Having an underlying haematological pathology. 3. Absence of signature of the informed consent by the 2 parents or the holder of parental authority. 4. Having received prior hematological treatments. 5. Parents with physical or mental condition not allowing to understand informed consent.
💊

What it tests

  • Biological sampling in patients
  • Biological sampling in control patients
📍

Where

3 sites
Service d'hématologie biologique-CHRU TOURS
Tours, France
Service d'onco-hématologie pédiatrique -CHRU Tours
Tours, France
Service de chirurgie orthopédique pédiatrique -CHRU TOURS
Tours, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy